XFRA ISIN CHANGE

Realtime	Geld	Brief	Zeit
	9,650	9,900	10:54

Realtime

Geld

Brief

Zeit

9,650

9,900

10:54

Einstellung Aufnahme
ISIN Name Einstellung mit Ablauf: ISIN Name Ab dem: Anmerkungen
CA39261L2049 Green Battery Minerals Inc. 23.06.2025 CA3194101067 First Canadian Grahite Inc. 24.06.2025 Tausch 1:1
US15117F8077 Cellectar Biosciences Inc. 23.06.2025 US15117F8804 Cellectar Biosciences Inc. 24.06.2025 Tausch 30:1
CA75103L1013 Rakovina Therapeutics Inc. 23.06.2025 CA75103L3092 Rakovina Therapeutics Inc. 24.06.2025 Tausch 10:1
KYG3472Y1017 FIH Mobile Ltd. 23.06.2025 KYG3472Y1199 FIH Mobile Ltd. 24.06.2025 Tausch 10:1
US38000Q2012 Crescent Biopharma Inc. 23.06.2025 KYG2545C1042 Crescent Biopharma Inc. 24.06.2025 Tausch 1:1

Epische Goldpreisrallye

Der Goldpreis hat ein neues Rekordhoch überschritten. Die Marke von 3.500 US-Dollar ist gefallen, und selbst 4.000 US-Dollar erscheinen nur noch als Zwischenziel.

Die Rallye wird von mehreren Faktoren gleichzeitig getrieben:

· massive Käufe durch Noten- und Zentralbanken
· Kapitalflucht in sichere Häfen
· hohe Nachfrage nach physisch besicherten Gold-ETFs
· geopolitische Unsicherheit und Inflationssorgen

Die Aktienkurse vieler Goldproduzenten und Explorer sind in den vergangenen Wochen regelrecht explodiert.

Doch es gibt noch Titel, die Nachholpotenzial besitzen. In unserem kostenlosen Spezialreport erfahren Sie, welche 3 Goldaktien jetzt besonders aussichtsreich sind und warum der Aufwärtstrend noch lange nicht vorbei sein dürfte.

Laden Sie jetzt den Spezialreport kostenlos herunter und profitieren Sie von der historischen Gold-Hausse.

Dieses Angebot gilt nur für kurze Zeit – also nicht zögern, jetzt sichern!

Hier klicken

Zeit	Aktuelle Nachrichten
Fr	Cellectar Biosciences beschafft 5,8 Mio. US-Dollar über Optionsscheine
Di	Cellectar Biosciences enters into agreements to raise $5.8M
Di	Cellectar Biosciences, Inc. Enters Into Agreements to Raise $5.8 Million
06.10.	Cellectar Biosciences, Inc. - 8-K, Current Report
06.10.	Cellectar Biosciences, Inc.: Cellectar Biosciences Announces European Medicines Agency (EMA) Confirms Eligibility to File for Conditional Marketing Authorization (CMA) for Iopofosine I 131 as a Treatment for Refractory (post-BTKi) ...	Following Scientific Advice and Guidance from Scientific Advice Working Party (SAWP) of EMA, Submission of CMA Application for Iopofosine I 131 as a Treatment for Refractory (post-BTKi) WM Expected... ► Artikel lesen

Zeit

Aktuelle Nachrichten

Cellectar Biosciences beschafft 5,8 Mio. US-Dollar über Optionsscheine

Cellectar Biosciences enters into agreements to raise $5.8M

Cellectar Biosciences, Inc. Enters Into Agreements to Raise $5.8 Million

06.10.

Cellectar Biosciences, Inc. - 8-K, Current Report

06.10.

Cellectar Biosciences, Inc.: Cellectar Biosciences Announces European Medicines Agency (EMA) Confirms Eligibility to File for Conditional Marketing Authorization (CMA) for Iopofosine I 131 as a Treatment for Refractory (post-BTKi) ...

Following Scientific Advice and Guidance from Scientific Advice Working Party (SAWP) of EMA, Submission of CMA Application for Iopofosine I 131 as a Treatment for Refractory (post-BTKi) WM Expected...
► Artikel lesen

Zeit	Aktuelle Nachrichten
02.10.	XFRA C68: WIEDERAUFNAHME/RESUMPTION	FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen
27.08.	Stifel reiterates Buy rating on Crescent Biopharma stock at $28 target
25.08.	Jefferies startet Coverage für Crescent Biopharma mit Kaufempfehlung und hohem Kursziel
25.08.	Jefferies initiates coverage on Crescent Biopharma stock with Buy rating
31.07.	Crescent Biopharma Reports Second Quarter 2025 Financial Results and Recent Business Highlights	Completed Merger with GlycoMimetics and Previously Announced $200 Million Private Financing Supporting Pipeline of Next Generation Therapeutics for Solid Tumors Recent Leadership Appointments Bring... ► Artikel lesen

Zeit

Aktuelle Nachrichten

02.10.

XFRA C68: WIEDERAUFNAHME/RESUMPTION

FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME...
► Artikel lesen

27.08.

Stifel reiterates Buy rating on Crescent Biopharma stock at $28 target

25.08.

Jefferies startet Coverage für Crescent Biopharma mit Kaufempfehlung und hohem Kursziel

25.08.

Jefferies initiates coverage on Crescent Biopharma stock with Buy rating

31.07.

Crescent Biopharma Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Completed Merger with GlycoMimetics and Previously Announced $200 Million Private Financing Supporting Pipeline of Next Generation Therapeutics for Solid Tumors Recent Leadership Appointments Bring...
► Artikel lesen

Zeit	Aktuelle Nachrichten
24.09.	FIH (02038): NEXT DAY DISCLOSURE RETURN
18.09.	FIH (02038): LETTER TO NON-REGISTERED SHAREHOLDERS AND REPLY FORM - NOTICE OF PUBLICATION OF INTERIM REPORT 2025 AND ARRANGEMENT OF ELECTRONIC DISSEMINATION ...
18.09.	FIH (02038): LETTER TO REGISTERED SHAREHOLDERS AND REPLY FORM - NOTICE OF PUBLICATION OF INTERIM REPORT 2025 AND ARRANGEMENT OF ELECTRONIC DISSEMINATION ...
18.09.	FIH (02038): INTERIM REPORT 2025
12.09.	FIH (02038): NEXT DAY DISCLOSURE RETURN

Zeit

Aktuelle Nachrichten

24.09.

FIH (02038): NEXT DAY DISCLOSURE RETURN

18.09.

FIH (02038): LETTER TO NON-REGISTERED SHAREHOLDERS AND REPLY FORM - NOTICE OF PUBLICATION OF INTERIM REPORT 2025 AND ARRANGEMENT OF ELECTRONIC DISSEMINATION ...

18.09.

FIH (02038): LETTER TO REGISTERED SHAREHOLDERS AND REPLY FORM - NOTICE OF PUBLICATION OF INTERIM REPORT 2025 AND ARRANGEMENT OF ELECTRONIC DISSEMINATION ...

18.09.

FIH (02038): INTERIM REPORT 2025

12.09.

FIH (02038): NEXT DAY DISCLOSURE RETURN

Zeit	Aktuelle Nachrichten
03.10.	First Canadian Graphite Inc: First Canadian talks Volt Carbon's second U.S. patent
03.10.	First Canadian Graphite Inc.: Congratulations to Volt Carbon Technologies on Second U.S. Patent and Graphene Achievement
03.09.	First Canadian Graphite Inc: First Canadian talks up Berkwood resource estimate
02.09.	First Canadian Graphite Inc. Corporate Update
29.08.	First Canadian Graphite Inc: First Canadian 4,672,500-share private placement

Zeit

Aktuelle Nachrichten

03.10.

First Canadian Graphite Inc: First Canadian talks Volt Carbon's second U.S. patent

03.10.

First Canadian Graphite Inc.: Congratulations to Volt Carbon Technologies on Second U.S. Patent and Graphene Achievement

03.09.

First Canadian Graphite Inc: First Canadian talks up Berkwood resource estimate

02.09.

First Canadian Graphite Inc. Corporate Update

29.08.

First Canadian Graphite Inc: First Canadian 4,672,500-share private placement

Zeit	Aktuelle Nachrichten
29.08.	Rakovina Therapeutics reports Q2 results
29.08.	Rakovina Therapeutics Inc: Rakovina Therapeutics Announces Three-Month Q2 ended June 30, 2025 Financial Results and Provides Corporate Update	VANCOUVER, British Columbia, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. ("Rakovina" or the "Company") (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing cancer therapies... ► Artikel lesen
26.08.	Rakovina Therapeutics Inc: Rakovina Therapeutics CSO Dr. Mads Daugaard Invited to Present at the 13th Tuscany Retreat on Cancer Research and Apoptosis
12.08.	Rakovina Therapeutics Inc (2): Rakovina Therapeutics signs LOI for JV with NanoPalm
12.08.	Rakovina Therapeutics Inc: Rakovina Therapeutics and NanoPalm Ltd. Sign Letter of Intent to Form Joint Venture Leveraging AI-Discovered Oncology Therapies and Novel Lipid Nanoparticle Delivery Technologies	VANCOUVER, British Columbia and RIYADH, Saudi Arabia, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. ("Rakovina" or the "Company") (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company... ► Artikel lesen

Zeit

Aktuelle Nachrichten

29.08.

Rakovina Therapeutics reports Q2 results

29.08.

Rakovina Therapeutics Inc: Rakovina Therapeutics Announces Three-Month Q2 ended June 30, 2025 Financial Results and Provides Corporate Update

VANCOUVER, British Columbia, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. ("Rakovina" or the "Company") (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing cancer therapies...
► Artikel lesen

26.08.

Rakovina Therapeutics Inc: Rakovina Therapeutics CSO Dr. Mads Daugaard Invited to Present at the 13th Tuscany Retreat on Cancer Research and Apoptosis

12.08.

Rakovina Therapeutics Inc (2): Rakovina Therapeutics signs LOI for JV with NanoPalm

12.08.

Rakovina Therapeutics Inc: Rakovina Therapeutics and NanoPalm Ltd. Sign Letter of Intent to Form Joint Venture Leveraging AI-Discovered Oncology Therapies and Novel Lipid Nanoparticle Delivery Technologies

VANCOUVER, British Columbia and RIYADH, Saudi Arabia, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. ("Rakovina" or the "Company") (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company...
► Artikel lesen

Unternehmen / Aktien	Kurs	%
CELLECTAR BIOSCIENCES INC	4,630	0,00 %
CRESCENT BIOPHARMA INC	9,550	-1,04 %
FIH MOBILE LTD	1,900	-2,56 %
FIRST CANADIAN GRAPHITE INC	0,075	-17,58 %
RAKOVINA THERAPEUTICS INC	0,171	+2,40 %

Unternehmen / Aktien

Kurs

CELLECTAR BIOSCIENCES INC

4,630

0,00 %

CRESCENT BIOPHARMA INC

9,550

-1,04 %

FIH MOBILE LTD

1,900

-2,56 %

FIRST CANADIAN GRAPHITE INC